Dendritic cells in the skin–potential use for melanoma treatment
/in International Publications, Malignant Melanoma /von 2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-41Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
/in HIV/AIDS, International Publications /von 2008-11-26 / Clin. Vaccine Immunol. 2009 Feb;16(2):233-40Recent advances in cancer vaccines: an overview
/in Dendritic Cells, International Publications /von 2008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-80Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
/in International Publications, Malignant Melanoma /von 2008-11-15 / Clin. Cancer Res. 2008 Nov;14(22):7358-66Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
/in International Publications, Malignant Melanoma /von 2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-50Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
/in Breast Cancer, Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients
/in Cervical Cancer, International Publications /von 2008-11-05 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):242-50Dendritic cell vaccines for the treatment of prostate cancer
/in International Publications, Prostate Cancer /von 2008-11-01 / Urol. Oncol. 2008 Nov-Dec;26(6):576-80[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
/in International Publications, Malignant Melanoma /von 2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-8
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution